Cross-cultural adaptation and validation of the Brazilian version of the Scleroderma Health Assessment Questionnaire (SHAQ)

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP ROCHA, Luiza F. FMUSP-HC
STEEN, Virginia
KOWALSKI, Sergio C. 2014
dc.identifier.citation CLINICAL RHEUMATOLOGY, v.33, n.5, p.699-706, 2014
dc.identifier.issn 0770-3198
dc.description.abstract The Scleroderma Health Assessment Questionnaire (SHAQ) is a feasible multisystem specific tool that has been extensively used as an additional assessment for systemic sclerosis (SSc). The aim of this study is to cross-culturally adapt and validate the Brazilian version of the SHAQ. Construct validity was assessed based on the correlations between SHAQ and both the Medical Outcomes Survey Short Form 36 version 2 (SF-36v2 (TM)) and the Health Assessment Questionnaire Disability Index (HAQ-DI). The correlation between the SHAQ and disease severity was assessed by Spearman's correlation coefficient. The reproducibility of the SHAQ was evaluated by the intraclass correlation coefficient (ICC). Among the 151 consecutive outpatients evaluated, 59 % had limited SSc subtype. The overall disease severity visual analog scale (VAS) of the SHAQ was statistically significantly correlated to HAQ-DI, pain VAS, and the SF-36v2 (TM) physical component summary score (r = 0.595, r = 0.612, and r = -0.582, respectively; p < 0.001). Further analysis of all SF-36v2 (TM) components revealed statistically significant correlations between overall disease severity VAS and bodily pain (r = -0.621, p < 0.001), vitality (r = -0.544, p < 0.001), physical function (r = -0.510, p < 0.001), and role limitation-physical dimensions (r = -0.505, p < 0.001). Moreover, digestive, pulmonary, and overall disease severity VASs were statistically significantly correlated to the number of organs involved (r = 0.178, p = 0.029; r = 0.214, p = 0.008; r = 0.282, p < 0.001). We also demonstrated high reproducibility for SHAQ (ICC = 0.757, 95 % confidence interval = 0.636-0.842). The Brazilian version of the SHAQ demonstrated both construct and discriminant validities as well as good reproducibility.
dc.language.iso eng
dc.relation.ispartof Clinical Rheumatology
dc.rights restrictedAccess
dc.subject Health Assessment Questionnaire; Quality of life; SF-36; Systemic sclerosis
dc.subject.other quality-of-life; systemic-sclerosis; disability index; medical outcomes; sf-36; classification; diseases; ability; scales; trial
dc.title Cross-cultural adaptation and validation of the Brazilian version of the Scleroderma Health Assessment Questionnaire (SHAQ)
dc.type article
dc.rights.holder Copyright SPRINGER LONDON LTD LIM/17
dc.identifier.doi 10.1007/s10067-013-2370-8
dc.identifier.pmid 23975361
dc.type.category original article
dc.type.version publishedVersion ROCHA, Luiza F.:FM: SAMPAIO-BARROS, Percival D.:HC:ICHC LEVY-NETO, Mauricio:HC:ICHC YOSHINARI, Natalino H.:FM:MCM BONFA, Eloisa:FM:MCM · MARANGONI, Roberta G.:Northwestern Univ, Div Rheumatol, Chicago, IL 60611 USA
· STEEN, Virginia:Georgetown Univ, Div Rheumatol, Washington, DC 20007 USA
· KOWALSKI, Sergio C.:McMaster Univ, Fac Hlth Sci, Hamilton, ON, Canada 2-s2.0-84902363299 WOS:000335401500016 LONDON ENGLAND
hcfmusp.relation.reference · CHACKO KA, 1995, CIRCULATION, V92, P2003
· Charles C, 2006, LANCET, V367, P1683, DOI 10.1016/S0140-6736(06)68737-0
· Ciconelli R.M., 1999, REV BRAS REUMATOL, V39, P143
· Clements PJ, 2001, ARTHRITIS RHEUM, V44, P653, DOI 10.1002/1529-0131(200103)44:3<653::AID-ANR114>3.0.CO;2-Q
· Clements Philip J., 1995, Current Opinion in Rheumatology, V7, P517
· Cohen J, 2003, APPL MULTIPLE REGRES, P703
· Danieli E, 2005, CLIN RHEUMATOL, V24, P48, DOI 10.1007/s10067-004-0970-z
· FERRAZ MB, 1990, J RHEUMATOL, V17, P813
· FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202
· FRIES JF, 1982, J RHEUMATOL, V9, P789
· Georges C, 2005, CLIN RHEUMATOL, V24, P3, DOI 10.1007/s10067-004-0942-3
· Hudson M, 2009, J RHEUMATOL, V36, P1226, DOI 10.3899/jrheum.081057
· Hudson M, 2009, ARTHRIT RHEUM-ARTHR, V61, P1112, DOI 10.1002/art.24676
· Johnson SR, 2005, ARTHRIT RHEUM-ARTHR, V53, P256, DOI 10.1002/art.21084
· Khanna D, 2005, J RHEUMATOL, V32, P832
· Khanna D, 2007, ARTHRITIS RHEUM, V56, P1676, DOI 10.1002/art.22580
· Kuwana M, 2003, J RHEUMATOL, V30, P1253
· La Montagna G, 2006, Reumatismo, V58, P112
· Laguardia J, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-61
· LEROY EC, 1988, J RHEUMATOL, V15, P202
· Ostojic P, 2006, Z RHEUMATOL, V65, P168, DOI 10.1007/s00393-006-0050-7
· Pope J, 2011, ARTHRIT CARE RES, V63, pS98, DOI 10.1002/acr.20598
· Ramos-Casals M, 2010, NAT REV RHEUMATOL, V6, P269, DOI 10.1038/nrrheum.2010.48
· Rannou F, 2007, ARTHRIT RHEUM-ARTHR, V57, P94, DOI 10.1002/art.22468
· Ruof J, 1999, RHEUMATOLOGY, V38, P535, DOI 10.1093/rheumatology/38.6.535
· Silman A, 1998, J RHEUMATOL, V25, P79
· Smyth AE, 2003, RHEUMATOLOGY, V42, P732, DOI 10.1093/rheumatology/keg145
· Poole J L, 1991, Arthritis Care Res, V4, P27, DOI 10.1002/art.1790040106
· Steen VD, 1997, ARTHRITIS RHEUM, V40, P1984, DOI 10.1002/art.1780401110
· Tektonidou MG, 2011, NAT REV RHEUMATOL, V7, P708, DOI 10.1038/nrrheum.2011.157
· Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012
· Ware J. E., 2000, SF 36 HLTH SURVEY MA
· WARE JE, 1995, MED CARE, V33, pAS264
· Wild D, 2005, VALUE HEALTH, V8, P94, DOI 10.1111/j.1524-4733.2005.04054.x
dc.description.index MEDLINE
dc.identifier.eissn 1434-9949
hcfmusp.citation.scopus 2
hcfmusp.citation.wos 3 Brasil Canadá Estados Unidos

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account